#United States #New Orleans #CBL-514 #Caliway Biopharma #GLP-1R Therapy

Presentation of CBL-514 at ADA 2026

Caliway Biopharmaceuticals, a prominent player in the biopharmaceutical sector, is set to unveil groundbreaking preclinical research on their fat reduction candidate, CBL-514, at the American Diabetes Association's 2026 Scientific Sessions. This significant event will take place from June 5 to 8 in New Orleans, Louisiana, and it draws global experts in diabetes and metabolic health. The selection of this research underscores the innovative potential of CBL-514, particularly in combination with GLP-1 receptor (GLP-1R) based weight-loss therapies.

The Significance of the ADA Scientific Sessions

The ADA's Scientific Sessions is renowned as one of the most influential gatherings in the field of diabetes research, attracting over 12,000 professionals, including researchers, physicians, and dietitians. It serves as a premier platform to showcase cutting-edge research and clinical advancements in diabetes treatment and management. This year, Caliway's presentation will be made by Dr. W. Timothy Garvey, a leading authority in obesity and metabolic medicine, who serves as a scientific advisor for the company. Dr. Garvey's involvement, given his prestigious standing in the medical community, will significantly enhance Caliway's visibility within the industry.

Research Highlights: CBL-514 in Combination with GLP-1R Therapy

Caliway's selected abstract, titled "Combination of Tirzepatide with CBL-514 an Adipocyte-Apoptosis Agent Improves Weight Loss Durability and Adipose Tissue Remodeling in Diet-Induced Obese Rats," delivers promising insights into how CBL-514 could revolutionize weight management solutions. The combination therapy addresses key challenges in weight loss by effectively promoting adipocyte apoptosis, which potentially leads to sustained fat reduction and improved metabolic outcomes. Recent preclinical findings suggest that when CBL-514 is used alongside GLP-1R therapies, there may be synergistic effects that benefit not just weight loss but overall metabolic health.

Engaging with Global Experts

Caliway is seizing this opportunity to directly engage with international experts, academics, and pharmaceutical representatives who attend the ADA conference. These interactions aim to deepen their strategic development and foster collaborations that enhance the development of CBL-514. By presenting its latest findings, Caliway also seeks to affirm its commitment to advancing weight management therapies and establishing a strong foothold in this competitive field.

About CBL-514 and Caliway Biopharmaceuticals

CBL-514 is a pioneering injectable lipolysis drug that uniquely targets subcutaneous fat reduction without the systemic safety concerns typically associated with weight-loss medications. It is designed to yield localized results, making it a valuable option in aesthetic medicine and metabolic disorder management. To date, Caliway has successfully completed ten clinical trials, involving over 544 participants, all of which have achieved primary efficacy and safety objectives.

As it continues to explore multiple indications for CBL-514, such as treating moderate-to-severe cellulite, the company's vision is to position itself as an innovative leader in the pharmaceutical landscape, especially in aesthetic medicine. With the combination of research excellence and strategic partnerships, Caliway is set to make a significant impact on the global obesity treatment market.

For further inquiries, visit Caliway Biopharmaceuticals.